DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Pentetate Zinc (Pentetate Zinc Trisodium Injection) - Drug Interactions, Contraindications, Overdosage, etc

 
 



DRUG INTERACTIONS

Carcinogenesis, Mutagenesis, Impairment of Fertility

Studies with Zn-DTPA to evaluate carcinogenesis, mutagenesis and impairment of fertility have not been performed. Data for Zn-DTPA effects on spermatogenesis are not available.

Teratogenic Effects

Pregnancy Category B

There are no human pregnancy outcome data from which to assess the risk of Zn-DTPA exposure on fetal development. Reproduction studies have been performed in pregnant mice at doses up to 11.5 mmol/kg (31 times the recommended daily dose of 1 gram based on body surface area [BSA] adjusted dose) and have revealed no evidence of impaired fertility or harm to the fetus. There was a slight reduction in the average birth weight.

Treatment of pregnant women should begin and continue with Zn-DTPA. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. The risk of toxicity from untreated internal radioactive contamination should be weighed against the risk of Zn-DTPA treatment.

OVERDOSAGE

Overdose with Zn-DTPA has not been reported.

CONTRAINDICATIONS

None known.

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017